Clinical

Dataset Information

0

A phase II basket study of necitumumab for EGFR amplification positive m etastatic solid tumor : WJOG15021M


ABSTRACT: Interventions: Necitumumab 800 mg, IV over 60 minutes, given o n days 1 and 8, repeated every 3 weeks Primary outcome(s): Objective response rate: ORR Study Design: single arm study, open(masking not used), uncontrolled control, single assignment, treatment purpose

DISEASE(S): Esophageal Cancer, Gastric Cancer, Small Intestine Cancer, Urothelial Cancer, Breast Cancer

PROVIDER: 78984 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2015-02-12 | GSE61234 | GEO
2022-06-04 | PXD030072 | Pride
| S-EPMC4076442 | biostudies-literature
2023-03-11 | PXD037267 | Pride
| 2614542 | ecrin-mdr-crc
2006-01-06 | GSE3975 | GEO
2015-02-12 | GSE61235 | GEO
2013-03-19 | GSE45300 | GEO
2017-02-22 | GSE87748 | GEO
2017-02-22 | GSE87747 | GEO